S. Mechanism of impaired growth hormone r".r"tio" in patients with Cushing's disease.
Patients with Cushing's disease show blunted growth hormone (GH) responses in various provocative tests
including insulin-induced hypoglycemia (1, 2)' arginine loading (f ), ana L-dopa loading (3) . Smals et al' (4) reported that they also show a reduced GH response to growth hormone-release hormone (GHRH). The reason for impaired GH secretion in patients with Cushing's disease is, however, still unknown, and there are no reports of studies on the functional change of their GHRH-GH axis.
We found previously that the GHRH Ievel in the plasma increased before or simultaneously with increase in GH secretion during slow wave sleep or oral L-dopa loading (5) , indicating that oral L-dopa should be useful as stimuli in GHRH provocative tests (6) . Therefore, in this work, to elucidate the mechanism of impairment of GH secretion in patients with Cushing's disease' we studied the function of their GHRH-GH axis by analysing (a) the GH responses of the patients to GHRH loading and L-dopa loading, (b) the GHRH response to I-dopa Ioading, and (c) the daytime profile of their plasma GH concentration. Plasma GH was measured with a highly sensitive immunoradiometric assay (IRMA).
Materials and methods

Subjects
As shown in Table 1 , one male and six female patients with Cushing's disease (aged 29-51 years) were studied.
Cushing's disease was diagnosed on the basis of the symptoms, Iaboratory findings and pituitary imaging.
Five patients had received no therapy, and two patients had undergone transsphenoidal adenomectomy but with insufficient effect. AII the patients had hypercortisolemia. Tests on GHRH Ioading and L-dopa loading were performed at rest after overnight fasting'
As controls, 10 age-matched subjects (33-51 years) and 12 normal elderly subiects (70-8 5 years) were also studied.
The study was approved by the Human Subjects Protection Committee, School of Medicine, University of Tokushima. and informed consent was obtained from the patients.
GHRH test
A dose of 100 prg of synthetic GHRH (1-44)NH, (GRF Sumitomo 100: Sumitomo Pharmaceutical Co', Osaka, Japan) was administered intravenously and before and 15, 30, 60, 90 and 120 min after its administration blood samples were collected in pre-cooled polypropy-Iene tubes containing 7.2 mg EDTA and 500 KIU aprotinin per ml of blood. The plasma was separated and stored at -40oC until assay of plasma GH concentration.
L-dopa loading test
A dose of 500 mg of L-dopa (Daiichi Pharmaceutical Co., Tokyo, Japan) was given orally and blood samples were collected at 0, 30, 60, 90 and 120 min for determinations of plasma GHRH and GH concentrations. 
Determination of plasma GH
Plasma GH concentration was measured using a radioimmunoassay (RIA) kit, HGH-II (Dianabot Co., Tokyo, fapan). The sensitivity of the assay was O.3 pgll and the intraand interassay coefficients of variation were 5.7-6.3/o and 3.4-5.6%, respectively (6) . The daytime profile of plasma GH concentration was determined with a highly sensitive GH IRMA kit (Daiichi Radioisotope Institute D-9111). The lower detection limit was O.Ol 1qll, and the intraand interassay coefficients of variation were 5.7/o and 6.8/o, respectively (7, 8) .
Determination of plasma GHRH
Plasma GHRH concentration was determined using the double antibody method reported previously (9), For plasma GHRH extraction, 1 ml of plasma was acidified with 80 pl of solution containing 80% 1N HCl, 5% formic acid, 1/o trifluoro-acetic acid (TFA), and 1/o NaCl.
Then it was applied to a Sep-Pak Cl8 cartridge, and washed in 0.1% TFA; the material was eluted in 9O 
Results
Plasma GH response to GHRH loading The plasma GH levels in the seven patients with Cushing's disease increased from a basal value of 1.1* O.7 pell to 6.313.2 (2.8-12. 2) pell after the administration of GHRH (f -44)NH2. This response was signifi_ cantly (p<O.01) lower than that of 10 age-matihed controls aged 33-51 years (basal value 1.g +O.3 pglt; peak value 29.114.7 pell) (Fie. 1). There was no significant difference between the plasma GH responses of the patients and 12 elderly normal subjects aged 70-85 years (basal value 0.9 +O2 pell; peak value 7o.7 t2.3 psll). 
Discussion
In this study, we demonstrated that GHRH release in response to L-dopa loading in patients with Cushing's disease is similar to that in age-matched subjects, and that the patients show low levels of pulsatile GH secretion during daytime. Studies on the plasma GHRH level measured by RIA have shown that after L-dopa Ioading an increase in plasma GHRH occurs after a rise in the plasma GH level (5, (11) (12) (13) (14) in normal subiects, but did not in patients with hypothalamic disorders (12)' In rats, immunohistochemical study has demonstrated that the L-dopa neurons are mainly present in the arcuate nucleus, together with abundant GHRH neurons (15) . These data strongly suggest that L-dopa loading stimulates GH secretion from the hypothalamus, and is thus useful as a GHRH provocative test. Interestingly, we found that after L-dopa Ioading the increase in plasma GHRH in the patients with Cushing's disease with hypercortisolemia was similar to that in age-matched controls, but that the response of their plasma GH was blunted. This indicates Plasma GH response to L-dopa loading After oral administration of L-dopa, the plasma GH concentrations in the age-matched controls increased from a basal value of 1.3+0.1 pgllto a peak value of 18.6+ 7.O pgllin 30-90 min, whereas those of patients did not increise significantly (basal value l'6+O'7 ttgll; peak value 2.2+0.6 Pell) (Fie.2).
Plasma GHRH response to L-dopa loading
As shown in Fig. 3 , the plasma GHRH concentration in patients with Cushing's disease increased significantly i.ou basal value of 1 8.9 t 1 .5 ng/l to 3 
